Advanced Renal Disease Clinical Trials
Renal Cell Carcinoma
Advanced Disease
Salvage Therapy
Adjuvant Therapy
Laboratory Correlates
In Development
Advanced Disease
Front Line: A Phase II Study of Sutent and Gemcitabine in Patients with Poor Risk and Sarcomatoid RCC
Industry sponsored, Phase II trial open to poor risk and sarcomatoid RCC without prior targeted therapy.
Salvage Therapy
Avator Trial
A single arm, Phase II trial of the combination of Bevacizumab and Temsirolimus in patients with metastatic RCC who have progressed on VEGF TKI therapy.
A Phase II Biomarker Trial of Everolimus in Patients with Advanced Renal Cell Carcinoma
There will be no limit to number of prior therapies, but patients cannot have received prior mTOR inhibitors. Patients must have at least one site of biopsiable disease.
Adjuvant Therapy
None open at this time
Laboratory Correlates
Analysis of Discarded Tissue in Patients with Renal Cell Carcinoma Undergoing Either Nephrectomy or Resection of Metastatic Disease
Tumor tissue in stored in our Tissue Bank to be analyzed by gene expression profiling and various immunohistochemical and RT-PCR techniques in an effect to discover new prognostic factors, predictors of response and resistance and new therapeutic targets.
(SPORE Project 4)
Collection of Specimen and Clinical Data From Patients with Renal Cell Carcinoma
Tissue banking and database protocol (SPORE PATH CORE)
Development
none at this time
